Business Wire

CA-CONFLUENT

12.5.2021 09:02:04 CEST | Business Wire | Press release

Share
Confluent Launches Confluent for Kubernetes, the Fastest Path to Building a Private Cloud Apache Kafka Service for Data in Motion

Confluent, Inc. , the platform to set data in motion, today announced Confluent for Kubernetes , the first platform purpose-built to bring cloud-native capabilities to data streams in private infrastructures. To make it easier and faster to harness the value of data in motion across an entire organization, Confluent drew on its expertise managing thousands of Apache Kafka® clusters in Confluent Cloud to offer the same cloud-native experience for on-premises environments. These cloud-native capabilities are key to running modern data platforms and are now available wherever an organization’s applications and data reside. Within minutes, it’s now possible to build a private cloud Kafka service that powers applications that are increasingly critical to how organizations thrive.

To win in today’s global economy, organizations must deliver exceptional customer experiences and data-driven, backend operations. This requires the ability to react, respond, and adapt to a continuous, ever-changing flow of data from across an organization in real time. This has driven the rapid rise of Kafka as a key enabler to helping companies cut across silos and process the flow of business events as they happen. However, given the high level of technical complexity, need for constant monitoring, and time-consuming custom tooling, self-managing Kafka is difficult and often takes large teams of specialized professionals. These challenges can result in costly project delays and inefficient resource investments, holding organizations back as they compete to innovate and win in a digital-first world.

“To compete in the digital realm, organizations need to quickly deliver personalized customer experiences and real-time operations, which are only possible with access to data from all environments and cloud-native advantages,” said Ganesh Srinivasan, Chief Product and Engineering Officer, Confluent. “For organizations that need to operate on premises, we’re bringing the benefits of cloud computing to their private infrastructure with Confluent for Kubernetes. Now, any company can build a private cloud service to move data across their business regardless of its environment.”

Confluent for Kubernetes – Bringing Benefits From the Leading Data in Motion Cloud Platform to On-Premises Environments

With the launch of Confluent for Kubernetes, Confluent brings together the cloud-native advantages learned from Confluent Cloud with the control and customization from self-managing their private infrastructure in on-premises environments. So whether an organization is transitioning to the cloud or needs to keep workloads on premises, they can take full advantage of Confluent for Kubernetes’ cloud-native capabilities, including a declarative API to deploy and operate Confluent. The platform also makes moving applications to the public cloud easier by seamlessly migrating workloads to wherever your business needs them with the ability to connect and share data with Confluent Cloud. By reimagining what is possible for private infrastructure with the capabilities of modern cloud computing, it is easier than ever for organizations to build and manage a private cloud Kafka service for moving data across a business.

  • Enhanced reliability As a cloud-native system, Confluent for Kubernetes intelligently detects if a process fails and will automatically restart processes or reschedule as necessary. Automated rack awareness spreads replicas of a partition across different racks, improving the availability of your brokers and limiting the risk of data loss. With automated reliability, organizations can minimize the risk of business disruption, reduce downtime costs, and limit data loss.
  • Automated elasticity Meet changing business demands with the ability to scale up using API-driven operations. The platform will automatically generate configurations, schedule and run new broker processes, and ensure data is balanced across brokers so that clusters can be efficiently utilized. With the ability to spin up and down Confluent clusters, organizations can control infrastructure costs while quickly scaling to meet their business needs.
  • Simplified infrastructure management A core concept of the cloud-native paradigm is the ability to focus on higher value activities that create business value rather than performing complex sequences of low-level infrastructure-related operations. Confluent for Kubernetes extends the Kubernetes API, enabling organizations to define the desired high-level state of clusters rather than manage all the low-level details. This infrastructure-as-code approach reduces operational burden and achieves a faster time to value, while enhancing security with standards that can be easily and consistently deployed across an organization.

Kafka Summit Europe 2021

Tune into Confluent Co-founder and CEO Jay Kreps’ keynote at Kafka Summit Europe on May 12 at 8:00 a.m. GMT to learn more about today’s news. Register now: https://kafkasummit.io/

For a deep dive into Confluent for Kubernetes, don’t miss this Kafka Summit Europe lightning talk happening today at 1 p.m. GMT: https://www.kafka-summit.org/sessions/gitops-for-kafka-with-confluent-for-kubernetes

Additional Resources

About Confluent

Confluent is pioneering a fundamentally new category of data infrastructure focused on data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io .

The preceding outlines our general product direction and is not a commitment to deliver any material, code, or functionality. The development, release, timing, and pricing of any features or functionality described may change. Customers should make their purchase decisions based upon services, features, and functions that are currently available. Confluent and associated marks are trademarks or registered trademarks of Confluent, Inc.

Apache® and Apache Kafka® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye